Skip to content
← Full study record

NCT00351468 · MORE INFO

Limitations, agreements, and source contact

EXTEND (Eltrombopag Extended Dosing Study) · Source last updated 2017-04-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
organization
Novartis
phone
862-778-8300
title
Study Director
Complete source fields
certain Agreement
other Details
Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
organization
Novartis
phone
862-778-8300
title
Study Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice